These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Rascol O Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400 [No Abstract] [Full Text] [Related]
47. [Hypersexuality during use of levodopa]. van Deelen RA; Rommers MK; Eerenberg JG; Egberts AC Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2095-8. PubMed ID: 12448966 [TBL] [Abstract][Full Text] [Related]
48. Medical treatment of Parkinson's disease. Ahlskog JE Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977 [No Abstract] [Full Text] [Related]
50. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? Bejjani BP; Arnulf I; Demeret S; Damier P; Bonnet AM; Houeto JL; Agid Y Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339 [TBL] [Abstract][Full Text] [Related]
51. Effective strategies in the management of Parkinson's disease. Wills AJ Hosp Med; 1998 Apr; 59(4):287-90. PubMed ID: 9722367 [TBL] [Abstract][Full Text] [Related]
52. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease]. Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756 [TBL] [Abstract][Full Text] [Related]
53. Recognition and treatment of response fluctuations in Parkinson's disease: review article. Verhagen Metman L Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528 [TBL] [Abstract][Full Text] [Related]
54. The management approaches to dyskinesia vary from country to country. Woitalla D; Mueller T; Russ H; Hock K; Haeger DA Neuroepidemiology; 2007; 29(3-4):163-9. PubMed ID: 18043000 [TBL] [Abstract][Full Text] [Related]
55. [Diagnosis and therapy of Parkinson's disease]. Wittstock M; Benecke R MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869 [TBL] [Abstract][Full Text] [Related]
56. Should levodopa be used anymore? Zegers de Beyl D Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242 [TBL] [Abstract][Full Text] [Related]
57. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?]. Wedekind S MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622 [No Abstract] [Full Text] [Related]
58. Levodopa-induced belly dancer's dyskinesias in Parkinson's disease: report of one case. Carecchio M; Collini A; Comi C; Cantello R; Bhatia KP; Monaco F Mov Disord; 2010 Aug; 25(11):1760-2. PubMed ID: 20645401 [No Abstract] [Full Text] [Related]
59. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Manson AJ; Iakovidou E; Lees AJ Mov Disord; 2000 Mar; 15(2):336-7. PubMed ID: 10752589 [No Abstract] [Full Text] [Related]
60. [Incidence and determinants of levodopa-induced dyskinesia in a retrospective cohort of Mexican patients with Parkinson's disease]. Cervantes-Arriaga A; Rodríguez-Violante M; Salmerón-Mercado M; Calleja-Castillo J; Corona T; Yescas P; Alonso-Vilatela E Rev Invest Clin; 2012; 64(3):220-6. PubMed ID: 23045943 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]